MDCLF

Healthcare Biotechnology

MedinCell S.A.

$34.39

+0.00 +0.00% today Live

Price History

Not enough data

Price chart data
Date	Price
Oct 5, 2026, live at 11:54 AM ET	34.39

Key Stats

Market Cap

1.24B

Avg Volume

EPS

-$0.67

52W High

$34.39

52W Low

$6.98

Div. Yield

0.0%

Valuation

P/B Ratio

357.20

P/S Ratio

50.89

EV/EBITDA

-60.99

EV/Revenue

50.34

Margins

Gross Margin 100.0%

Operating Margin (139.5%)

Net Margin (128.9%)

EBITDA Margin (82.5%)

Growth & Returns

Revenue Growth (YoY)

(44.6%)

Return on Assets

(13.1%)

Liquidity & Leverage

Current Ratio

4.67

Quick Ratio

4.59

Debt / Equity

23.47

Total Cash

84.82M

Total Debt

71.92M

About

MedinCell S.A. engages in the research and development of biodegradable polymer-based processes for the controlled and prolonged delivery of active pharmaceutical ingredients into the human body and animals in France. The company offers UZEDY, a subcutaneous risperidone for the treatment of schizophrenia. It also develops mdc-TJK, a subcutaneous injection, which is in NDA stage for the treatment of schizophrenia; and mdc-CWM, a sustained-release formulation of celecoxib, which is in Phase III clinical trial for the treatment and reduction of post-operative pain and inflammation. In addition, the company engages in the development of products in preclinical stage, including mdc-WWM for contraception; mdc-STM for the treatment of malaria; and mdc-AbbVie-1. It has strategic collaborations with TEVA, AIC, ABBVIE, Unitaid, and Gates Foundation. The company was incorporated in 2003 and is headquartered in Jacou, France.